Kiniksa Pharmaceuticals (NASDAQ:KNSA) Stock Price Up 9.3% - What's Next?

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Get Free Report) shares were up 9.3% during trading on Monday . The company traded as high as $21.74 and last traded at $22.16. Approximately 178,815 shares traded hands during mid-day trading, a decline of 68% from the average daily volume of 559,280 shares. The stock had previously closed at $20.28.

Analyst Ratings Changes

Separately, Wedbush restated an "outperform" rating and issued a $34.00 target price on shares of Kiniksa Pharmaceuticals in a research note on Tuesday, February 25th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus target price of $36.60.

Kiniksa Pharmaceuticals Stock Down 0.6 %

The company has a market cap of $1.54 billion, a PE ratio of -151.92 and a beta of 0.48. The business has a 50-day simple moving average of $19.73 and a 200-day simple moving average of $22.40.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last announced its earnings results on Tuesday, February 25th. The company reported ($0.12) EPS for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.06). Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The firm had revenue of $122.50 million for the quarter, compared to analyst estimates of $123.42 million. During the same period in the previous year, the company earned $0.35 EPS. Kiniksa Pharmaceuticals's revenue was up 46.9% compared to the same quarter last year. On average, research analysts forecast that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current fiscal year.

Remove Ads

Insider Activity at Kiniksa Pharmaceuticals

In related news, COO Eben Tessari sold 14,000 shares of the stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $19.57, for a total value of $273,980.00. Following the completion of the sale, the chief operating officer now owns 81,975 shares of the company's stock, valued at approximately $1,604,250.75. This trade represents a 14.59 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 54.57% of the company's stock.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in KNSA. Quarry LP acquired a new stake in shares of Kiniksa Pharmaceuticals in the third quarter valued at approximately $50,000. Lazard Asset Management LLC acquired a new stake in shares of Kiniksa Pharmaceuticals in the fourth quarter valued at approximately $61,000. KLP Kapitalforvaltning AS acquired a new stake in Kiniksa Pharmaceuticals during the fourth quarter worth $158,000. Bellevue Group AG acquired a new stake in Kiniksa Pharmaceuticals during the fourth quarter worth $160,000. Finally, Tower Research Capital LLC TRC increased its stake in Kiniksa Pharmaceuticals by 117.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 8,483 shares of the company's stock worth $168,000 after acquiring an additional 4,575 shares during the last quarter. Institutional investors and hedge funds own 53.95% of the company's stock.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.